Abiopharma

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Sofive Soccer Centers Selects Square to Power Its 22-Location National Footprint

Sweetening Americas 250th Birthday: General Mills Gifts 1 Million Free Betty Crocker Cakes

One NZ Future-Proofs Its Oracle Estate and Accelerates AI Innovation with Rimini Street

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Eason Technology Announces Management Share Purchase Plan, Demonstrate Confidence in the Companys Future

PubMatic Launches Creator Marketplace to Connect Content Creators with Emerging Agentic Demand

Tuya Inc. Announces Results of Annual General Meeting